In a filing, Ionis Pharmaceuticals Inc revealed its EVP CLO & General Counsel O’NEIL PATRICK R. unloaded Company’s shares for reported $0.11 million on Sep 12 ’25. In the deal valued at $64.58 per share,1,700 shares were sold. As a result of this transaction, O’NEIL PATRICK R. now holds 57,130 shares worth roughly $3.51 million.
Then, Baroldi Joseph sold 11,950 shares, generating $742,838 in total proceeds. Upon selling the shares at $62.16, the EVP, Chief Business Officer now owns 31,926 shares.
Before that, O’NEIL PATRICK R. sold 21,000 shares. Ionis Pharmaceuticals Inc shares valued at $1,355,661 were divested by the EVP CLO & General Counsel at a price of $64.56 per share. As a result of the transaction, O’NEIL PATRICK R. now holds 57,130 shares, worth roughly $3.51 million.
BMO Capital Markets upgraded its Ionis Pharmaceuticals Inc [IONS] rating to an Outperform from a a Market perform in a research note published recently. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who increased its forecast for the stock in late July from “an Equal-weight” to “an Overweight”. Barclays also remained covering IONS and has increased its forecast on July 01, 2025 with a “an Overweight” recommendation from previously “an Equal weight” rating. H.C. Wainwright started covering the stock on April 07, 2025. It rated IONS as “a Buy”.
Price Performance Review of IONS
On Monday, Ionis Pharmaceuticals Inc [NASDAQ:IONS] saw its stock jump 0.57% to $61.36. Over the last five days, the stock has gained 0.43%. Ionis Pharmaceuticals Inc shares have risen nearly 44.85% since the year began. Nevertheless, the stocks have risen 75.51% over the past one year. While a 52-week high of $64.71 was reached on 09/10/25, a 52-week low of $23.95 was recorded on 04/09/25.
Levels Of Support And Resistance For IONS Stock
The 24-hour chart illustrates a support level at 60.55, which if violated will result in even more drops to 59.73. On the upside, there is a resistance level at 62.68. A further resistance level may holdings at 63.99.
How much short interest is there in Ionis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Ionis Pharmaceuticals Inc stocks on 2025-08-29, dropping by -1.08 million shares to a total of 10.5 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 11.58 million shares. There was a decline of -10.26%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 31, 2025 when Redburn Atlantic began covering the stock and recommended ‘”a Neutral”‘ rating along with a $39 price target.
